These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18537959)

  • 1. Exenatide may aggravate moderate diabetic renal impairment: a case report.
    Johansen OE; Whitfield R
    Br J Clin Pharmacol; 2008 Oct; 66(4):568-9. PubMed ID: 18537959
    [No Abstract]   [Full Text] [Related]  

  • 2. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
    Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
    [No Abstract]   [Full Text] [Related]  

  • 3. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
    Charbonnel PB
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
    [No Abstract]   [Full Text] [Related]  

  • 4. Exenatide in type 2 diabetes.
    Verzegnassi F; Chinello M
    Lancet; 2010 Sep; 376(9746):1052-3; author reply 1053. PubMed ID: 20870094
    [No Abstract]   [Full Text] [Related]  

  • 5. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
    López-Ruiz A; del Peso-Gilsanz C; Meoro-Avilés A; Soriano-Palao J; Andreu A; Cabezuelo J; Arias JL
    Pharm World Sci; 2010 Oct; 32(5):559-61. PubMed ID: 20686848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide once weekly in type 2 diabetes.
    Scheen AJ
    Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
    Wenten M; Gaebler JA; Hussein M; Pelletier EM; Smith DB; Girase P; Noel RA; Braun DK; Bloomgren GL
    Diabet Med; 2012 Nov; 29(11):1412-8. PubMed ID: 22416857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
    Wajcberg E; Tavaria A
    Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide-associated ischemic renal failure.
    Weise WJ; Sivanandy MS; Block CA; Comi RJ
    Diabetes Care; 2009 Feb; 32(2):e22-3. PubMed ID: 19171732
    [No Abstract]   [Full Text] [Related]  

  • 14. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM
    Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 18. Longacting exenatide in diabetes: DURATION-3.
    Misra A; Joshi S
    Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
    [No Abstract]   [Full Text] [Related]  

  • 19. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
    Cohen D
    BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.
    Schwartz S
    Curr Med Res Opin; 2008 Nov; 24(11):3009-22. PubMed ID: 18828960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.